Get the Stockscreener App
4.93
9.04%
-0.49
After Hours:
4.93
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $4.93, with a volume of 2.69M.
It is down -9.04% in the last 24 hours and down -7.50% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$5.42
Open:
$5.37
24h Volume:
2.69M
Relative Volume:
1.08
Market Cap:
$2.00B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-10.27
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
-8.87%
1M Performance:
-7.50%
6M Performance:
-49.12%
1Y Performance:
-36.96%
1-Day Range:
$4.9212
$5.385
1-Week Range:
$4.9212
$5.595
52-Week Range:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.93 | 2.00B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch Health price target cut to $8 by Raymond James - Investing.com UK
Dry Eye Syndrome Treatment Market Set to Witness Significant - openPR.com
BHC: RBC Capital Raises Price Target for Bausch Health Companies | BHC Stock News - GuruFocus
Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Bausch Health Companies First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Psoriasis Market: Epidemiology, Therapies, Companies, - openPR.com
RBC on Bausch Health's Q1 - marketscreener.com
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Bausch Health Companies Inc. SEC 10-Q Report - TradingView
Bausch Health Reports Q1 2025 Financial Results - TipRanks
Bausch Health Companies Q1 2025 Earnings Call Transcript - MarketBeat
Bausch: Q1 Earnings Snapshot - MySA
Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Bausch Health Companies Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bausch Health Q1 2025 slides: revenue up 6%, EBITDA grows 14% excluding B+L - Investing.com
Bausch Health Companies Inc. 2025 Q1ResultsEarnings Call Presentation (NYSE:BHC) - Seeking Alpha
Bausch Health Down 3.8% After Hours as It Reports a Lower Q1 Adjusted Profit - marketscreener.com
Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing - TipRanks
Bausch Health (BHC) Pre-Earnings Options Activity Indicates Anti - GuruFocus
Bausch Health Reports 8th Consecutive Growth Quarter, Completes $7.9B Refinancing Deal - Stock Titan
Bausch Health Announces First Quarter 2025 Results - The Globe and Mail
Bausch + Lomb Brief: Updating FY25 Guidance to Reflect Estimated One-Time Impact of enVista Intraocular Lenses Voluntary Recall and Impact of FX - marketscreener.com
Health Canada approves Bausch Health’s skin tightening device - Investing.com
Bausch Health Companies Q1 2025 Earnings Preview - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Bausch Health Companies Inc. (BHC) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Hyperopia Market, Epidemiology, Therapies, Companies, - openPR.com
Bausch Health's Skin Tightening System Gets Health Canada Clearance - marketscreener.com
BHC Receives Canadian Approval for Advanced Thermage FLX Device - GuruFocus
Bausch Health Announcing Health Canada Clearance of Solta Medical's Thermage FLX System - marketscreener.com
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System - voiceofalexandria.com
Revolutionary Skin Tightening Device Thermage FLX Gets Health Canada Green Light: 25% Faster Treatments - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Onychomycosis Drug Market Emerging Trends and Growth Prospects - openPR.com
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares - MSN
Bausch Health jumps after Carl Icahn’s 34% stake - MSN
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. - ACCESS Newswire
Bausch Health unveils new skin resurfacing laser at ASLMS 2025 - Investing.com
Bausch Health unveils new skin resurfacing laser at ASLMS 2025 By Investing.com - Investing.com Canada
Future of Eye Health: Macular Degeneration Treatment Market - openPR.com
Bausch Health (BHC) Set to Launch Next-Gen Fraxel FTX at Key Con - GuruFocus
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM) - Weatherford Democrat
Facial Rejuvenation Market Report 2025-2034: Industry - openPR.com
Bausch Health says Carl Icahn has exposure to about 34% of company's shares - MSN
Bausch Health Learns Icahn Has 34% Economic Interest in Shares - MSN
Is Bausch Health Companies Inc. (BHC) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):